** Shares of biopharma co Halozyme Therapeutics HALO.O rise 2.7% to $59.70
** Merck's MRK.N injectable version of its blockbuster cancer drug Keytruda could face a potential patent challenge from Halozyme, the Wall Street Journal reports
** According to HALO, new version of Keytruda infringes on its patents, the report says
** Injectable version of Keytruda is still in clinical testing and expected to be launched by early 2026
** Stock has risen 42% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。